CDK4 and melanoma: The killing is unlikely to result from the D92A substitution in P16P1 that increases its CDK4-inhibitory activity (Fåhraeus et al., 1996), as the p16 peptides of Noonan et al. (2005) also killed melanoma cells, yet lacked that substitution.